Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia

被引：0
作者：
H. Donath
S. Woelke
R. Schubert
M. Kieslich
M. Theis
G. Auburger
R. P. Duecker
S. Zielen
机构：
[1] Goethe University,Division of Allergology, Pulmonology and Cystic Fibrosis, Department for Children and Adolescents
[2] Goethe University,Division of Pediatric Neurology, Department for Children and Adolescents
[3] Goethe University,Experimental Neurology, Medical School
来源：
The Cerebellum | 2022年 / 21卷
关键词：
Ataxia telangiectasia; Neurofilament light chain; NfL; Neurodegeneration; Disease progression; Biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Ataxia telangiectasia (A-T) is a progressive and life-limiting disease associated with cerebellar ataxia due to progressive cerebellar degeneration. In addition to ataxia, which is described in detail, the presence of chorea, dystonia, oculomotor apraxia, athetosis, parkinsonism, and myoclonia are typical manifestations of the disease. The study aimed to evaluate the specificity and sensitivity of neurofilament light chain (NfL) as a biomarker of neurodegeneration in relation to SARA score. In this prospective trial, one visit of 42 A-T patients aged 1.3–25.6 years (mean 11.6 ± 7.3 years) was performed, in which NfL was determined from serum by ELISA. Additionally, a neurological examination of the patients was performed. Blood was collected from 19 healthy volunteers ≥ 12 years of age. We found significantly increased levels of NfL in patients with A-T compared to healthy controls (21.5 ± 3.6 pg/mL vs. 9.3 ± 0.49 pg/mL, p ≤ 0.01). There was a significant correlation of NfL with age, AFP, and SARA. NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.
引用
收藏
页码：39 / 47
页数：8
相关论文
共 459 条
[1]  
Boder E(1958)Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection Pediatrics 21 526-554
[2]  
Sedwick RP(2020)Diabetes in patients with ataxia telangiectasia: a national cohort study Front Pediatr 8 317-399
[3]  
Donath H(2014)Infections of the respiratory system in patients with ataxia-telangiectasia Pediatr Pulmonol 49 389-581
[4]  
Hess U(2015)Merkus PJ; European Respiratory Society. ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia Eur Respir Rev 24 565-507
[5]  
Kieslich M(2019)Hematopoietic stem cell transplantation restores naïve T-cell populations in Atm-deficient mice and in preemptively treated patients with ataxia-telangiectasia Front Immunol 10 2785-110
[6]  
Theis M(2013)Bone marrow transplantation improves the outcome of Atm-deficient mice through the migration of ATM-competent cells Hum Mol Genet 22 493-166
[7]  
Ohlenschläger U(2018)Pre-emptive allogeneic hematopoietic stem cell transplantation in ataxia telangiectasia Front Immunol 29 2495-88
[8]  
Schubert R(2018)Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with dexamethasone PLoS One 13 e0195388-5234
[9]  
Woelke S(2018)A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers Transfus Med Rev 32 102-180
[10]  
Zielen S(2018)In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia Mol Cell Biochem 438 153-55
12345678910